世界卫生组织对BPaLM方案治疗耐多药结核病指南的解读OA北大核心CSTPCD

Multidrug-resistant tuberculosis(MDR-TB)remains a significant risk for human health,and the World Health Organization has recently recommended a 6-month treatment regimen(BPaLM)with bedaquiline(Bdq),pretomanid(Pa),linezolid(Lzd)and moxifloxacin(Mfx)to treat MDR-TB.The new regimen not only extend the short-course program to MDR-TB patients,but also apply to tuberculosis with extensive lesions and most extrapulmonary tuberculosis,which is undoubtedly an important event in the treatment of MDR-TB.This article briefly introduces research history,population and considerations of BPaLM regimen.